IIT Madras Bharat Cancer Genome Atlas: First-of-Its-Kind Resource for Paediatric Leukaemia, Colorectal, and Pancreatic Cancers in India

Transforming Cancer Research with India-Specific Genomic Insights

The Bharat Cancer Genome Atlas (BCGA), launched by the Indian Institute of Technology Madras (IIT Madras), marks a groundbreaking advancement in oncology research tailored to the Indian population. Announced on February 4, 2026, coinciding with World Cancer Day, this first-of-its-kind resource compiles whole genome sequencing data from Indian patients suffering from paediatric leukaemia, colorectal cancer, and pancreatic cancer. By making this database publicly available at bcga.iitm.ac.in, IIT Madras is empowering researchers and clinicians worldwide to uncover genetic variants unique to Indians, paving the way for precision medicine that addresses local genetic diversity.

Unlike global databases like The Cancer Genome Atlas (TCGA), which predominantly feature Western populations, BCGA highlights mutations prevalent in India. This is crucial because genetic profiles can vary significantly due to ancestry, lifestyle, and environmental factors. For instance, certain driver mutations in these cancers may differ, influencing diagnosis and treatment efficacy. The initiative stems from the Indian Cancer Genome Programme initiated in 2020 at IIT Madras's Centre of Excellence on Cancer Genomics and Molecular Therapeutics, funded generously by Hyundai Motor India Foundation with over ₹56 crore.

Addressing India's Alarming Cancer Burden

India faces a staggering cancer crisis, with the Indian Council of Medical Research (ICMR) estimating that one in nine Indians will develop cancer in their lifetime. In 2022 alone, there were approximately 1.46 million new cases, projected to rise by 12.8% annually. Currently, over 2.5 million people live with the disease, straining healthcare resources. Among these, paediatric leukaemia, colorectal, and pancreatic cancers pose severe threats due to high incidence and poor survival rates.

Paediatric leukaemia, primarily Acute Lymphoblastic Leukaemia (ALL), is the most common childhood cancer in India, accounting for about 25-30% of paediatric malignancies with roughly 10,000-15,000 new cases yearly among children under 15. Colorectal cancer incidence stands at around 61,000 cases per GLOBOCAN 2022 data, rising with Westernized diets and urbanization. Pancreatic cancer, one of the deadliest, sees about 46,000 new cases annually, with a five-year survival rate below 10% due to late diagnosis.

• Leukaemia: Influences 59,000 total cases/year, high paediatric burden.
• Colorectal: 61,000 cases, mortality 49,000.
• Pancreatic: 46,000 cases, nearly matching mortality at 42,000.

These statistics underscore the urgency for localized genomic data, as treatments calibrated for Caucasian genetics often underperform in Indians.

Understanding the Bharat Cancer Genome Atlas

The BCGA serves as a national repository of cancer genomic data, focusing on whole genome sequencing (WGS). WGS involves extracting DNA from tumor and normal tissues, fragmenting it, sequencing billions of base pairs using next-generation sequencers, and aligning reads to the human reference genome to identify somatic mutations, structural variants, and copy number alterations.

Step-by-step process:

1. Sample collection from diverse Indian patients via partner hospitals like KK Childs Trust Hospital and Institute of Child Health in Chennai.
2. Tumor-normal paired sequencing at IIT Madras's biobank.
3. Bioinformatics analysis to catalog variants.
4. Integration into cBioPortal for visualization and querying.

The current release encompasses around 1,500 sequenced samples across cancers, including key datasets for the three focus areas. For example, the Colorectal Cancer Study at IITM includes 146 tumor samples and 47 germline, enabling queries on mutation frequencies.

Spotlight on Paediatric Leukaemia Genomics

Paediatric leukaemia genomics in BCGA reveals India-specific subtypes of ALL, characterized by genetic events like ETV6-RUNX1 fusions or hyperdiploidy, but with higher frequencies of Ph-like ALL in South Asians. This database aids in identifying biomarkers for risk stratification, crucial since Indian children show distinct relapse patterns. Early detection via these variants could improve survival from current 70-80% to over 90% with targeted therapies like tyrosine kinase inhibitors.

Real-world impact: Clinicians can now cross-reference patient genomes against BCGA to predict chemotherapy response, reducing toxic overtreatment.

Photo by Sunny Kumar on Unsplash

Insights into Colorectal and Pancreatic Cancer Variants

Colorectal cancer samples in BCGA highlight APC, KRAS, and TP53 mutations, but with elevated microsatellite instability in Indian cohorts linked to dietary spices and infections. Pancreatic adenocarcinoma datasets uncover KRAS G12D dominance and novel fusions absent in TCGA, informing immunotherapy candidates.

These findings promise population-tailored screening panels.

Technological Backbone: cBioPortal Integration

BCGA leverages cBioPortal, an open-source platform for exploring multidimensional cancer genomics data. Users can visualize OncoPrints of mutations, survival plots, and network views without coding expertise. This democratizes access, allowing research assistants and students to contribute to analyses.

Collaborations Driving Innovation

IIT Madras partners with Karkinos Healthcare for the National Center for Precision Medicine in Cancer, Hyundai for funding and camps, and hospitals for samples. Prof. V. Kamakoti emphasized, “This fills a critical gap in India’s genomic landscape.” Prof. S. Mahalingam highlighted biomarker discovery potential.

The Bharat Cancer Genome Grid (BCG2) complements BCGA by translating data to clinics via molecular tumor boards and training.

Implications for Precision Oncology and Public Health

BCGA shifts India from generic to personalized treatments, potentially reducing mortality by 20-30% through targeted drugs. Stakeholder perspectives: Oncologists gain tools for variant interpretation; patients benefit from equitable care via mobile units; policymakers can prioritize funding.

Photo by Gayatri Malhotra on Unsplash

• Benefits: Early detection kits, drug repurposing.
• Challenges: Data privacy, scalability.
• Solutions: Ethical frameworks, AI augmentation.

Career Opportunities in Cancer Genomics at IIT Madras

This launch opens doors for bioinformaticians, geneticists, and clinicians. IIT Madras's initiatives align with India's biotech boom, offering roles in sequencing and analysis. Aspiring professionals can explore higher ed research jobs, academic CV tips, or India university jobs. Programs like these foster interdisciplinary talent.

Future Outlook and Global Contributions

BCGA plans expansions to more cancers, AI-driven predictions, and international collaborations. By inviting data submissions, it builds a dynamic resource. For India's youth, this exemplifies higher education's societal impact, inspiring STEM pursuits amid rising postdoc opportunities.

In summary, IIT Madras's BCGA is a beacon for equitable cancer care. Explore rate my professor, higher ed jobs, career advice, and university jobs to join this revolution. Stay engaged with comments below.